Exchange: NASDAQ·Updated 07:30 PM EST

QTTB News

News
all
press releases
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in LondonPR NewswireWALTHAM, Mass., Nov. 11, 2026 WALTHAM, Mass., Nov. 11, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a...
PR Newswire
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in LondonPR NewswireWALTHAM, Mass., Nov. 11, 2026 WALTHAM, Mass., Nov. 11, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a...
PR Newswire
More News
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireWALTHAM, Mass., Nov. 4, 2026 -- Presented additional 36-week results and 16-week off-drug findings from Part B of the...
PR Newswire
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a...
PR Newswire
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the...
PR Newswire
Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development OfficerPR NewswireWALTHAM, Mass., Sept. 14...
PR Newswire
The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Sept. 1, 2026 WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company...
PR Newswire
The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Aug. 5, 2026 -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical...
PR Newswire
The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks

Advertisement|Remove ads.